The buzz around psilocybin as a potential longevity intervention faces a reality check from an unexpected angle: the lifespans of its most prominent advocates. While mushroom compounds have shown promise in extending mouse lifespans, translating these findings to humans requires more than laboratory optimism. Researchers compared mortality data from 11 prominent psychedelic personalities, researchers, and advocates who openly discussed their psychedelic use against 12 cancer researchers and 5 aging researchers. All groups significantly exceeded general population life expectancy, reflecting the substantial longevity advantages that come with higher education, economic privilege, and career access to cutting-edge health knowledge. However, the psychedelic advocates showed no survival advantage over their scientific peers studying cancer or aging research. The analysis represents an unconventional but pragmatic approach to evaluating early longevity claims. Rather than waiting decades for controlled trials, examining real-world outcomes among long-term users offers immediate insights, albeit with obvious limitations. The psychedelic research community has historically attracted health-conscious individuals with access to premium healthcare and lifestyle advantages that independently promote longevity. This demographic confounding makes it nearly impossible to isolate any compound-specific effects from observational data. The findings underscore a critical gap in psychedelic longevity research: mechanistic studies in mice generate excitement, but human applications remain speculative without rigorous epidemiological evidence. The authors advocate for systematic population studies and controlled trials before making therapeutic claims about psychedelic anti-aging effects, representing a measured scientific approach to an increasingly hyped field.